ZA997288B - Azithromycin combination for emesis control in dogs. - Google Patents

Azithromycin combination for emesis control in dogs.

Info

Publication number
ZA997288B
ZA997288B ZA9907288A ZA997288A ZA997288B ZA 997288 B ZA997288 B ZA 997288B ZA 9907288 A ZA9907288 A ZA 9907288A ZA 997288 A ZA997288 A ZA 997288A ZA 997288 B ZA997288 B ZA 997288B
Authority
ZA
South Africa
Prior art keywords
dogs
macrolide antibiotic
antagonist
substance
azithromycin
Prior art date
Application number
ZA9907288A
Other languages
English (en)
Inventor
Richard Todd Darrington
Dennis Michael Godek
Elizabeth Leigh Fraerin Illyes
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA997288B publication Critical patent/ZA997288B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9907288A 1999-01-29 1999-11-24 Azithromycin combination for emesis control in dogs. ZA997288B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11787699P 1999-01-29 1999-01-29

Publications (1)

Publication Number Publication Date
ZA997288B true ZA997288B (en) 2001-05-24

Family

ID=22375307

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9907288A ZA997288B (en) 1999-01-29 1999-11-24 Azithromycin combination for emesis control in dogs.

Country Status (12)

Country Link
US (3) US20020016301A1 (de)
EP (1) EP1027892B1 (de)
JP (1) JP2000219640A (de)
KR (1) KR20000052444A (de)
AT (1) ATE302013T1 (de)
AU (1) AU6065799A (de)
CA (1) CA2290771A1 (de)
DE (1) DE69926722D1 (de)
HU (1) HUP9904393A2 (de)
IL (1) IL133077A0 (de)
NZ (1) NZ501211A (de)
ZA (1) ZA997288B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521368A (en) * 2000-03-28 2004-05-28 Biochemie Ges M Granulated particles of an active compound, with a film-forming coating resulting in the masked taste of said active compound
GB0315671D0 (en) * 2003-07-04 2003-08-13 Chelsea And Westminster Nhs Tr Improvements in or relating to organic compounds
US9486467B2 (en) 2006-06-12 2016-11-08 Ramot At Tel-Aviv University Ltd. Method of treating colorectal cancer that expresses a mutated APC gene by administering erythromycin or tylosin
US20110172262A1 (en) 2008-09-15 2011-07-14 Biovista, Inc. Compositions and methods for treating epilepsy
US9795601B2 (en) * 2010-12-15 2017-10-24 Biovista, Inc. Compositions and methods for cancer treatment
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
KR20230155155A (ko) * 2022-05-03 2023-11-10 녹십자수의약품 주식회사 마크로라이드 계열 항생제를 유효성분으로 포함하는 개과 동물의 호흡기 질환의 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833236A (en) * 1986-05-02 1989-05-23 Taisho Pharmaceutical Co., Ltd. Erythromycin derivatives
EP0533280B2 (de) * 1991-09-20 2004-12-01 Glaxo Group Limited Neue medizinische Indikation für Tachykinin-Antagonisten
MX9308001A (es) * 1992-12-21 1994-08-31 Lilly Co Eli Premezcla para piensos de animales que contiene tilosina y procedimiento para su obtencion.
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
FR2740335B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p
CA2189501A1 (en) * 1995-11-06 1997-05-07 Harry R. Howard Nk-1 receptor antagonists for the treatment of cancer
US5958888A (en) * 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions

Also Published As

Publication number Publication date
EP1027892A2 (de) 2000-08-16
ATE302013T1 (de) 2005-09-15
HUP9904393A2 (en) 2002-09-28
NZ501211A (en) 2001-10-26
IL133077A0 (en) 2001-03-19
US20040063649A1 (en) 2004-04-01
KR20000052444A (ko) 2000-08-25
HU9904393D0 (en) 2000-01-28
JP2000219640A (ja) 2000-08-08
EP1027892B1 (de) 2005-08-17
US20030018049A1 (en) 2003-01-23
US20020016301A1 (en) 2002-02-07
EP1027892A3 (de) 2002-06-19
AU6065799A (en) 2000-08-03
CA2290771A1 (en) 2000-07-29
DE69926722D1 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
NZ335825A (en) Use of azithromycin for treating atherosclerosis
AP2001002142A0 (en) 13-membered azalides and their use as antibiotic agents.
ATE161265T1 (de) Derivate von 16-gliedrigen antibiotischen macroliden
ZA997288B (en) Azithromycin combination for emesis control in dogs.
GR3006180T3 (de)
HUP0300585A3 (en) Process for the use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals
MX9708611A (es) Compuestos de dialquiltiacumicina.
DE69402714T2 (de) Amid-derivate von 16-gliedrige heterocyclen als antibiotische macrolide
HU9403502D0 (en) 9 a-n-(n`-carbamoyl) and 9 a-n-(n`-thiocarbamoyl) derivatives 9-deoxo-9a-aza-9a-homoerythro-mycin a
IL101394A0 (en) New compounds,named"leustroducins",their preparation and their therapeutic use
EP1227721A4 (de) Neue substituierte bernsteinsäure metall-beta-lactamase-inhibitoren und ihre verwendung zur behandlung von bakteriellen infektionen
AU3515193A (en) Antimicrobial carbapenem derivatives, their preparation and their therapeutic use
WO1990006307A3 (en) Antibacterial quinolone compounds
GR3003852T3 (de)
EP0416327A3 (en) Chemical derivatives of antibiotics ll-e19020 alpha and beta
WO2000078772A3 (en) Antibiotic agents
IN164553B (de)
MX9803694A (es) Derivados de 3-desoxi-3-desclandinosa de eritromicinas a y b.
ES2076107A1 (es) Derivados de antibioticos macrolidos de anillos de 16 miembros.
UA22243A (uk) Спосіб лікуваhhя локальhих гhійhо-запальhих захворюваhь
IT1313628B1 (it) Uso di compositi di fluorochinolone contro batteri dell'apparatorespiratorio